162 related articles for article (PubMed ID: 28761747)
1. Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).
Orditura M; Gravina A; Riccardi F; Diana A; Mocerino C; Leopaldi L; Fabozzi A; Giordano G; Nettuno R; Incoronato P; Barzelloni ML; Caputo R; Pisano A; Grimaldi G; Genua G; Montesarchio V; Barbato E; Iodice G; Lieto E; Procaccini E; Mabilia R; Febbraro A; Laurentiis M; Ciardiello F
ESMO Open; 2017; 2(2):e000176. PubMed ID: 28761747
[TBL] [Abstract][Full Text] [Related]
2. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
O'Shaughnessy J; McIntyre K; Schwartzberg L; Wilks S; Puhalla S; Berrak E; Song J; Vahdat L
Springerplus; 2015; 4():532. PubMed ID: 26413438
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.
Gui X; Liang X; Li H
Cancer Med; 2023 Aug; 12(16):16793-16804. PubMed ID: 37403746
[TBL] [Abstract][Full Text] [Related]
4. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
Zhao Y; Xie N; Li W; Chen W; Lv Z; Zheng Y; Sun T; Liu J; Zhang J; Hu S; Wang Y; Gong C; Li Y; Xie Y; Ge R; Xu F; Wang B
Ther Adv Med Oncol; 2021; 13():17588359211030210. PubMed ID: 34290830
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
7. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
8. [Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer].
Sang D; Song LH; Di LJ; Wang YL; Liu CG; Guo ZQ; Liu QY; Wang H; Li SY; Yuan P
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):364-369. PubMed ID: 35448926
[No Abstract] [Full Text] [Related]
9. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
12. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V; Ricciardi GRR; Giuffrida D; Scandurra G; Russo A; Blasi L; Spadaro P; Iacono C; Soto Parra HJ; Savarino A; Ferraú F; Zerilli F; Verderame F; Butera A; Santangelo C; Franchina V; Caruso M
Ther Adv Med Oncol; 2019; 11():1758835919895755. PubMed ID: 31903098
[TBL] [Abstract][Full Text] [Related]
13. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
17. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.
Gamucci T; Michelotti A; Pizzuti L; Mentuccia L; Landucci E; Sperduti I; Di Lauro L; Fabi A; Tonini G; Sini V; Salesi N; Ferrarini I; Vaccaro A; Pavese I; Veltri E; Moscetti L; Marchetti P; Vici P
J Cancer; 2014; 5(5):320-7. PubMed ID: 24723974
[TBL] [Abstract][Full Text] [Related]
18. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
19. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
20. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]